Annual EBITDA
$451.95 M
+$136.44 M+43.25%
31 December 2023
Summary:
Halozyme Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently $451.95 million, with the most recent change of +$136.44 million (+43.25%) on 31 December 2023. During the last 3 years, it has risen by +$298.98 million (+195.46%). HALO annual EBITDA is now at all-time high.HALO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$190.03 M
+$47.43 M+33.26%
30 September 2024
Summary:
Halozyme Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently $190.03 million, with the most recent change of +$47.43 million (+33.26%) on 30 September 2024. Over the past year, it has increased by +$60.69 million (+46.92%). HALO quarterly EBITDA is now at all-time high.HALO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$580.46 M
+$60.69 M+11.68%
30 September 2024
Summary:
Halozyme Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently $580.46 million, with the most recent change of +$60.69 million (+11.68%) on 30 September 2024. Over the past year, it has increased by +$173.12 million (+42.50%). HALO TTM EBITDA is now at all-time high.HALO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +43.3% | +46.9% | +42.5% |
| 3 y3 years | +195.5% | +148.1% | +107.0% |
| 5 y5 years | +861.3% | +966.9% | +2485.5% |
HALO EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +195.5% | at high | +316.2% | at high | +126.0% |
| 5 y | 5 years | at high | +861.3% | at high | +740.1% | at high | +1029.4% |
| alltime | all time | at high | +668.7% | at high | +740.1% | at high | +714.7% |
Halozyme Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $190.03 M(+33.3%) | $580.46 M(+11.7%) |
| June 2024 | - | $142.60 M(+18.1%) | $519.77 M(+4.9%) |
| Mar 2024 | - | $120.74 M(-5.0%) | $495.45 M(+9.6%) |
| Dec 2023 | $451.95 M(+43.2%) | $127.09 M(-1.7%) | $451.95 M(+11.0%) |
| Sept 2023 | - | $129.34 M(+9.4%) | $407.33 M(+4.9%) |
| June 2023 | - | $118.28 M(+53.1%) | $388.42 M(+23.0%) |
| Mar 2023 | - | $77.24 M(-6.3%) | $315.80 M(+0.1%) |
| Dec 2022 | $315.51 M(+21.8%) | $82.47 M(-25.3%) | $315.51 M(+8.5%) |
| Sept 2022 | - | $110.42 M(+141.8%) | $290.67 M(+13.2%) |
| June 2022 | - | $45.66 M(-40.7%) | $256.86 M(-15.8%) |
| Mar 2022 | - | $76.95 M(+33.5%) | $305.20 M(+17.8%) |
| Dec 2021 | $259.04 M(+69.3%) | $57.64 M(-24.8%) | $259.04 M(-7.6%) |
| Sept 2021 | - | $76.61 M(-18.5%) | $280.49 M(+14.0%) |
| June 2021 | - | $94.00 M(+205.3%) | $245.94 M(+33.9%) |
| Mar 2021 | - | $30.79 M(-61.1%) | $183.64 M(+20.1%) |
| Dec 2020 | $152.96 M(-370.5%) | $79.08 M(+88.0%) | $152.96 M(+246.1%) |
| Sept 2020 | - | $42.06 M(+32.7%) | $44.19 M(-323.3%) |
| June 2020 | - | $31.70 M(>+9900.0%) | -$19.79 M(-68.3%) |
| Mar 2020 | - | $113.00 K(-100.4%) | -$62.46 M(+10.4%) |
| Dec 2019 | -$56.56 M(-4.7%) | -$29.69 M(+35.4%) | -$56.56 M(+132.4%) |
| Sept 2019 | - | -$21.92 M(+100.0%) | -$24.33 M(-4.1%) |
| June 2019 | - | -$10.96 M(-282.3%) | -$25.36 M(-20.4%) |
| Mar 2019 | - | $6.01 M(+137.1%) | -$31.87 M(-46.3%) |
| Dec 2018 | -$59.36 M(-169.2%) | $2.54 M(-111.0%) | -$59.36 M(-190.5%) |
| Sept 2018 | - | -$22.95 M(+31.4%) | $65.60 M(-33.0%) |
| June 2018 | - | -$17.47 M(-18.7%) | $97.92 M(+7.7%) |
| Mar 2018 | - | -$21.48 M(-116.8%) | $90.91 M(+6.0%) |
| Dec 2017 | $85.75 M(-207.9%) | $127.50 M(+1261.8%) | $85.75 M(-235.4%) |
| Sept 2017 | - | $9.36 M(-138.3%) | -$63.31 M(-33.0%) |
| June 2017 | - | -$24.47 M(-8.1%) | -$94.43 M(+4.2%) |
| Mar 2017 | - | -$26.64 M(+23.5%) | -$90.66 M(+14.1%) |
| Dec 2016 | -$79.47 M(+213.5%) | -$21.57 M(-0.9%) | -$79.47 M(+53.3%) |
| Sept 2016 | - | -$21.75 M(+5.1%) | -$51.83 M(-1.9%) |
| June 2016 | - | -$20.70 M(+34.0%) | -$52.83 M(+92.7%) |
| Mar 2016 | - | -$15.45 M(-354.2%) | -$27.42 M(+8.1%) |
| Dec 2015 | -$25.35 M(-58.5%) | $6.08 M(-126.7%) | -$25.35 M(-27.3%) |
| Sept 2015 | - | -$22.76 M(-582.9%) | -$34.87 M(+14.1%) |
| June 2015 | - | $4.71 M(-135.2%) | -$30.55 M(-38.5%) |
| Mar 2015 | - | -$13.39 M(+289.4%) | -$49.65 M(-18.7%) |
| Dec 2014 | -$61.03 M(-22.7%) | -$3.44 M(-81.4%) | -$61.03 M(-22.3%) |
| Sept 2014 | - | -$18.44 M(+28.2%) | -$78.52 M(+0.4%) |
| June 2014 | - | -$14.38 M(-42.0%) | -$78.22 M(-8.6%) |
| Mar 2014 | - | -$24.77 M(+18.4%) | -$85.61 M(+8.4%) |
| Dec 2013 | -$78.98 M | -$20.93 M(+15.4%) | -$78.98 M(+27.0%) |
| Sept 2013 | - | -$18.14 M(-16.7%) | -$62.17 M(-2.5%) |
| June 2013 | - | -$21.77 M(+20.0%) | -$63.75 M(+14.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$18.14 M(+340.1%) | -$55.74 M(+6.2%) |
| Dec 2012 | -$52.47 M(+181.0%) | -$4.12 M(-79.1%) | -$52.47 M(-21.1%) |
| Sept 2012 | - | -$19.72 M(+43.4%) | -$66.46 M(+60.7%) |
| June 2012 | - | -$13.75 M(-7.6%) | -$41.35 M(+70.7%) |
| Mar 2012 | - | -$14.88 M(-17.8%) | -$24.22 M(+29.7%) |
| Dec 2011 | -$18.67 M(-64.6%) | -$18.11 M(-436.0%) | -$18.67 M(+3.2%) |
| Sept 2011 | - | $5.39 M(+59.4%) | -$18.10 M(-49.1%) |
| June 2011 | - | $3.38 M(-136.2%) | -$35.56 M(-29.9%) |
| Mar 2011 | - | -$9.33 M(-46.8%) | -$50.71 M(-3.9%) |
| Dec 2010 | -$52.75 M(-7.5%) | -$17.54 M(+45.3%) | -$52.75 M(+11.1%) |
| Sept 2010 | - | -$12.07 M(+2.6%) | -$47.49 M(-3.1%) |
| June 2010 | - | -$11.76 M(+3.4%) | -$48.99 M(-9.2%) |
| Mar 2010 | - | -$11.38 M(-7.4%) | -$53.96 M(-5.4%) |
| Dec 2009 | -$57.01 M(+15.4%) | -$12.28 M(-9.5%) | -$57.01 M(-7.2%) |
| Sept 2009 | - | -$13.57 M(-18.9%) | -$61.47 M(+4.5%) |
| June 2009 | - | -$16.73 M(+16.0%) | -$58.82 M(+10.5%) |
| Mar 2009 | - | -$14.43 M(-13.8%) | -$53.21 M(+7.7%) |
| Dec 2008 | -$49.39 M(+79.1%) | -$16.74 M(+53.3%) | -$49.39 M(+16.6%) |
| Sept 2008 | - | -$10.92 M(-1.9%) | -$42.36 M(+7.0%) |
| June 2008 | - | -$11.13 M(+4.9%) | -$39.60 M(+15.8%) |
| Mar 2008 | - | -$10.61 M(+9.2%) | -$34.19 M(+24.0%) |
| Dec 2007 | -$27.57 M(+79.8%) | -$9.71 M(+19.1%) | -$27.57 M(+22.8%) |
| Sept 2007 | - | -$8.16 M(+42.9%) | -$22.46 M(+24.3%) |
| June 2007 | - | -$5.71 M(+43.0%) | -$18.06 M(+15.0%) |
| Mar 2007 | - | -$3.99 M(-13.1%) | -$15.71 M(+2.4%) |
| Dec 2006 | -$15.34 M(+14.9%) | -$4.60 M(+22.2%) | -$15.34 M(+7.5%) |
| Sept 2006 | - | -$3.76 M(+12.1%) | -$14.27 M(+0.3%) |
| June 2006 | - | -$3.36 M(-7.2%) | -$14.23 M(+3.4%) |
| Mar 2006 | - | -$3.62 M(+2.6%) | -$13.75 M(+3.0%) |
| Dec 2005 | -$13.36 M(+49.0%) | -$3.53 M(-5.2%) | -$13.36 M(+8.4%) |
| Sept 2005 | - | -$3.72 M(+29.0%) | -$12.32 M(+4.2%) |
| June 2005 | - | -$2.88 M(-10.4%) | -$11.82 M(+7.5%) |
| Mar 2005 | - | -$3.22 M(+29.4%) | -$11.00 M(+22.7%) |
| Dec 2004 | -$8.96 M(<-9900.0%) | -$2.49 M(-23.0%) | -$8.96 M(+64.7%) |
| Sept 2004 | - | -$3.23 M(+56.9%) | -$5.44 M(+109.3%) |
| June 2004 | - | -$2.06 M(+73.6%) | -$2.60 M(+190.1%) |
| Mar 2004 | - | -$1.19 M(-214.9%) | -$896.50 K(-1721.2%) |
| Dec 2003 | $0.00(0.0%) | $1.03 M(-366.3%) | $55.30 K(-105.8%) |
| Sept 2003 | - | -$387.70 K(+9.1%) | -$958.70 K(+64.3%) |
| June 2003 | - | -$355.20 K(+51.6%) | -$583.60 K(+136.6%) |
| Mar 2003 | - | -$234.30 K(-1366.5%) | -$246.70 K(<-9900.0%) |
| Dec 2002 | $0.00(-100.0%) | $18.50 K(-246.8%) | $0.00(-100.0%) |
| Sept 2002 | - | -$12.60 K(-31.1%) | -$18.50 K(+213.6%) |
| June 2002 | - | -$18.30 K(-247.6%) | -$5900.00(-147.6%) |
| Mar 2002 | - | $12.40 K | $12.40 K |
| Dec 2001 | -$39.70 K | - | - |
FAQ
- What is Halozyme Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual EBITDA year-on-year change?
- What is Halozyme Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly EBITDA year-on-year change?
- What is Halozyme Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM EBITDA year-on-year change?
What is Halozyme Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of HALO is $451.95 M
What is the all time high annual EBITDA for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $451.95 M
What is Halozyme Therapeutics annual EBITDA year-on-year change?
Over the past year, HALO annual earnings before interest, taxes, depreciation & amortization has changed by +$136.44 M (+43.25%)
What is Halozyme Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of HALO is $190.03 M
What is the all time high quarterly EBITDA for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $190.03 M
What is Halozyme Therapeutics quarterly EBITDA year-on-year change?
Over the past year, HALO quarterly earnings before interest, taxes, depreciation & amortization has changed by +$60.69 M (+46.92%)
What is Halozyme Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of HALO is $580.46 M
What is the all time high TTM EBITDA for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $580.46 M
What is Halozyme Therapeutics TTM EBITDA year-on-year change?
Over the past year, HALO TTM earnings before interest, taxes, depreciation & amortization has changed by +$173.12 M (+42.50%)